Saturday, September 22, 2018
“When I was diagnosed with breast cancer in 2003, I was ready to fight for my life, but I didn’t know about mouth sores or how hard they would make it for me.” Alex F. developed white, pus-filled sores only...
Results of a phase III clinical trial called KEYNOTE-189, presented at the Annual Meeting of the American Association for Cancer Research (AACR), held April 14-18., 2018, shows that patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer or...
As part of an international collaboration that looks to transform care for lung cancer patients the first patients have been enroll in a new cancer study at Avera, an integrated health system comprised of more than 330 locations in 100...
When a steady, relied-upon source of funding was ending, a public-private coalition of concerned stakeholders was created in Arizona to ensure that certain critical health care services could be continued. In June, Susan G. Komen’s Arizona affiliate announced via a...
As published in The Lancet Oncology this week, investigational data from the Phase I/II CHRYSALIS trial studying anti-leukemic activity and tolerability of gilteritinib, also known as ASP2215 (Astellas), supports the initiation of currently enrolling pivotal phase III ADMIRAL Trial. Gilteritinib...
During his first inaugural address in 1933, President Franklin D. Roosevelt famously said, “the only thing we have to fear is fear itself.” It was in the midst of the economic Depression and the newly elected president was trying to...
Palbociclib (Ibrance®; Pfizer) an oral agent that target cyclin-dependent kinases (CDK4 and CDK6), which appear to promote tumor cell proliferation in hormone-receptor positive breast cancer, is gaining notice for its ability to derail cancer cell growth, may also have...
Accounting for approximately 80% – 90% of all mesothelioma cases, malignant pleural mesothelioma or MPM is a rare but aggressive cancer. It is usually associated with occupational exposure to asbestos fibers and develops in the thin layer of tissue...
Excitement is growing for the treatment of patients with various forms of cancer using  immunotherapy — specific therapies that harness the power of a patient’s own immune system to combat their disease. The concept involves engineering chimeric antigen receptor ...
Findings from a phase III clinical trial funded by funded by F. Hoffmann-La Roche, point to a more effective initial treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). In the open label clinical trial (ALEX;...

Related articles